Skip to main content
European Commission logo
polski polski
CORDIS - Wyniki badań wspieranych przez UE
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary
Zawartość zarchiwizowana w dniu 2024-06-18

Development of a DNA vaccine for visceral leishmaniasis

Cel

This project will focus on the preclinical development of a DNA vaccine for human visceral leishmaniasis. The project is based upon the DNA vaccine technology and immunomodulators developed at Mologen AG (Berlin, Germany), which are in clinical development for cancer and 3-5 known antigens that already have demonstrated profiles of protection in animal models of leishmaniasis. Antigens will be selected on the basis of preset criteria to assure protection in high proportion of target populations and against many different species of Leishmania. In vitro and in vivo models will be used to evaluate the prophylactic and therapeutic efficacy of the DNA vehicle with selected antigens alone and in combination with and without immunomodulator. Full toxicology studies will be performed on selected candidate vaccines. Training in preclinical development and clinical trials (ICH-GCP) are an important part of the proposal. Sites will be selected and ready to initiate clinical trials at the end of this project (3 years).

Zaproszenie do składania wniosków

FP7-HEALTH-2007-B
Zobacz inne projekty w ramach tego zaproszenia

Koordynator

LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE ROYAL CHARTER
Wkład UE
€ 556 420,00
Adres
KEPPEL STREET
WC1E 7HT London
Zjednoczone Królestwo

Zobacz na mapie

Region
London Inner London — West Camden and City of London
Rodzaj działalności
Higher or Secondary Education Establishments
Kontakt administracyjny
Penny Ireland (Ms.)
Linki
Koszt całkowity
Brak danych

Uczestnicy (7)